×
Published on 29 April 2021

A testing ground to accelerate innovations

Do people like it and will they use it? Are there better outcomes? As simple as these questions may sound, there is no easy way to find the answers when it comes to developing new products. One possible approach to get the patient perspective on board and bring integrated Personalised Diabetes Management (iPDM) to life is through a recent agreement between Roche and Duke University in Durham, North Carolina (US). It is the first of its kind in which Roche Diabetes Care is partnering to establish a testbed for innovative products, services, and solutions for people with type 2 diabetes. 

With Duke collaborators, Roche Diabetes Care has a highly regarded institution at its side. The University's specialists will design, set up, and curate a well-characterised testing ground to enable the collection of feedback from people with type 2 diabetes as well as clinical stakeholders. Socioeconomic and clinical demographic information of the cohort established on the testbed will provide foundational steps that enable real-world feedback and will help build the evidence needed for diabetes digital health solutions.

“Over the next three years, the partnering will support our strategy to generate real-world evidence and bring more innovative solutions to the market for people with type 2 diabetes,” says Jim Lefevere, International Business Leader for Non-Insulin Therapy Solutions at Roche Diabetes Care. “Establishing a testbed with a well-known partner is a key next step in evaluating novel approaches and determining if users will adopt an innovative product. It will not only speed up evidence generation of how different personalised solutions for patients can drive better outcomes, but will also support innovation and piloting with external start-ups and digital health companies.”

Changing perspectives: Dr. Satasuk Joy Bhosai, who leads digital health innovation efforts at Duke, and Dr. Jennifer Green, an endocrinologist well known for research in the diabetes cardiometabolic space, are leading the effort through the Duke Clinical Research Institute. “The field of digital health is in dire need of partnerships that foster evidence-based interventions. Too much tech is being built without enough independently validated evidence to back up the claims. In order to improve care, we must evaluate impact and I’m thrilled that this partnership gives attention to developing meaningful technologies with and for patients,” says Dr. Bhosai.

This is the beginning of what we at Roche Diabetes Care hope will become a long-term partnership. The goal of the partnership is to enable a large pool of at least 500-1’000 participants who have consented to work with Roche and have already been recruited for research. This will help build the evidence needed for diabetes digital health solutions with the aim bring true relief to people living with type 2 diabetes. 
 

For more information contact: [email protected]